PCMK
NBIX icon

Paragon Capital Management (Kansas)’s Neurocrine Biosciences NBIX Stock Holding History

Paragon Capital Management (Kansas)’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-100
Closed -$9K – 277
2019
Q1 		$9K Buy
+100
New +$8.36K ﹤0.01% 169

Other funds holding NBIX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Paragon Capital Management (Kansas)'s NBIX Position: Q2 2019 in Review

Paragon Capital Management (Kansas) sold out of Neurocrine Biosciences (NBIX) in Q2 2019, closing a stake of 100 shares — an estimated $9K sold.

Paragon Capital Management (Kansas) first reported a position in NBIX in Q1 2019 and held it in 1 quarter. The position peaked at $9K in Q1 2019. 302 funds tracked by Wall St. Rank hold NBIX as of Q2 2019.

  • Paragon Capital Management (Kansas) reported no remaining Neurocrine Biosciences position as of Q2 2019 after selling out during the quarter.
  • Paragon Capital Management (Kansas) sold 100 Neurocrine Biosciences shares in Q2 2019, an estimated $9K.
  • Paragon Capital Management (Kansas) first reported a position in Neurocrine Biosciences in Q1 2019 and held it in 1 quarter.
  • Paragon Capital Management (Kansas)'s Neurocrine Biosciences position peaked at $9K in Q1 2019.
  • 302 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2019.

Based on Paragon Capital Management (Kansas)'s 13F filing for Q2 2019, filed 6 Aug 2019.